PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Advances in Cell Based Assays Offer Promise for the Discovery of New Drug Candidates - The drug discovery process has changed dramatically over the past decade and continues to evolve in response to new discoveries and technologies
Advances in Cell Based Assays Offer Promise for the Discovery of New Drug Candidates


NewswireToday - /newswire/ - London, United Kingdom, 2008/03/18 - The drug discovery process has changed dramatically over the past decade and continues to evolve in response to new discoveries and technologies.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


There is also increasing demand to produce more drug candidates and decrease attrition during drug development. Recent advances in cell culture robotic technology have grown out of the need to maximise efficiency and minimise the possibility of errors, contamination and failure associated with high-throughput cell culture.

In addition, the trends towards assay miniaturisation and multiplexing for high-throughput and ultrahigh-throughput have been triggered by the necessity to reduce development and operational costs. Despite advances in cell based assay technology, numerous bottlenecks still need to be addressed in drug discovery for the identification of novel drug candidates.

New analysis from Frost & Sullivan, European Cell Based Assays Markets, finds that the market for cell based assay kits earned revenues of $66.2 million in 2007 and estimates this to reach $220.1 in 2014.

As pharmaceutical companies strive to improve the cost effectiveness of their drug discovery programmes, it is becoming apparent that considerable amounts of money are lost on compounds that fail late in the drug discovery process because of their toxicity.

"Over the past decade, various initiatives have been taken to improve the science of predicting toxicity and improving extrapolation to humans, including the use of cell based assays to enhance predictions," notes Frost & Sullivan Research Analyst Dr. Laleh Safinia. "The revolution in the drug discovery process has recently demonstrated emerging lab disciplines and technology platforms in the area of cell based assay screening, holding great promise for the discovery of new drug targets."

Drug targets derived from genomics and proteomics projects have sparked the interest of pharmaceutical, biotechnology and drug discovery companies in screening large numbers of compounds using cell based assays in an ultrahigh-throughput format. Progress and advances in a number of technologies have made the utilisation of live cells in high-throughput screening and high-content screening assays an attractive option in the drug discovery process.

Partnerships and alliances between active participants within this industry will allow the acquisition of new molecules, increase profitability and offer a pipeline of other drugs in development as well as remove some of the bottlenecks within drug discovery.

Cell based assays are an important aspect of the drug discovery process. However, there is a growing need for reliable and robust assay kits to enable the effective standardisation of assays and a reduction in variability. For researchers using automated screening systems, the stability and compatibility of reagents with robotic components is often a concern, resulting in high cost of operation.

"The assay reagent must be stable at ambient temperature; signal generated by the assay should be stable for an adequate period of time to be able to monitor cells over a period of time," says Dr. Safinia. "Thus, HTS requires the optimisation of HTS assays and protocols. Approximately $200 million could be saved through more productive discovery programs or cell based assay screens that boost clinical success rates."

With the increase in demand for new drugs, the degree of competition among the drug discovery companies is also intensifying. The initial investment is considerable; however, the scope for new drug target and profit margins is also high.

"There is, therefore, a heightened need for target validation technology to verify the correct target through advances in assay protocols, novel technologies and reliable data analyses," comments Dr. Safinia. "Identifying the correct drug target through the use of genomics, proteomics and chemical libraries for drug discovery is a critical bottleneck in the pharmaceutical and biotechnology industries."

There have been tremendous efforts by the pharmaceutical industry to improve cell based screening platforms to expedite target validation as well as for use in preclinical trials. In order to understand the complexity of biological systems and accelerate the hit-to-lead process, recent advances in microfluidic technologies and automation have attracted a lot of attention with promising applications in cell based biosensors and drug screening.

In addition, considerable efforts are being made to improve the science of predicting the toxicology of emerging clinical candidates to reduce the ADME/Tox failure of drug candidates.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the European cell based assays markets, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.], with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

European Cell Based Assays Markets is part of the Drug Discovery Technologies Growth Partnership Service programme, which also includes research in the following markets: Contract Research Organisations (CROs) Markets in Europe, Nucleic Acid Isolation Markets in Europe and Advances in Laboratory Automation Markets in Europe. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

European Cell Based Assays Markets - M0E6

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Advances in Cell Based Assays Offer Promise for the Discovery of New Drug Candidates

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  La Bella Bakery Artisan Bakery Arizona

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (